Jun 2019         GMDx attending BIO2019 (Philadelphia, PA)


Jun 2019         Dr. Robyn Lindley invited to attend the iCancer International Cancer Conference and Expo 2019 (Baltimore, MA)

Dr. Lindley is presenting “The clinical importance of deaminase editing profiles for Innate Immune Fitness diagnostics (IIF.dx) in oncology”


May 2019        GMDx will be attending ASCO 2019 in Chicago, IL.


May 2019         GMDx attended Brisbane Immunotherapy 2019 (Brisbane, Australia)


May 2019         Key patent published: “Methods for predicting the efficacy of cancer therapy”


May 2019         Dr. Robyn Lindley invited to attend the World Cancer Congress (Osaka, Japan)

Dr. Lindley is presenting “The Identification of Cancer Progression Associated Signatures (C-PAS) for High Risk Patient Stratification”


Apr 2019         Publication linking differences in deaminase activity between mice, dogs and humans. Furthering our understanding why pre-clinical

trials involving mice or dogs may not yield results that are consistent with human clinical trial outcomes.


Mar 2019        Dr. Robyn Lindley invited to attend the prestigious Gordon Research Conference (Tuscany, Italy)

Dr. Lindley is presenting “The molecular mechanisms of transcription-linked editing by DNA and RNA deaminase mutators in cancer”


Feb 2019         Publication providing first evidence linking changes in T-helper cells with changes in the tumor microenvironment and changes in

deaminase signatures in late stage ovarian cancer.


Dec 2018        GMDx completed an “Accelerating Commercialisation” Grant awarded from the Department of Industry, Innovation and Science.

This grant supported development and patenting of methods for determining the likelihood of Hepatitis B virus recrudescence.


Dec 2018        GMDx appoints a new Chairman (Mr. Terry Sinclair) and Non-Executive Directors (Mr. Stephen Moulton & Mr. Greg Johnson): Bios


July 2018       Publication providing evidence that deaminases are a likely source of many SNPs in the human population.


Jun 2018        GMDx will be attending ASCO 2018 in Chicago, IL.


Apr 2018        GMDx receives an “Innovation Connections” grant from the Department of Industry, Innovation and Science.

 This grant will support a staff member placement with the Hudson Institute of Medical Research to conduct in vitro deaminase profiling.


Apr 2018        Key Patent Granted in Hong Kong

 Title: “Methods for determining the cause of somatic mutagenesis”


Mar 2018        GMDx attended the City of Melbourne Trade Mission to Osaka, Japan.

 GMDx attendees met with senior executives from some of Japan’s largest pharmaceutical companies and also with key collaborators at a   number of world-class clinical institutions.


Feb 2018        GMDx attended the Molecular Medicine Tri-Con in San Francisco, February 2018.


Feb 2018        Dr Robyn Lindley invited to speak at “Eradicate Cancer 2018” Conference in Melbourne (abstract).


Jan 2018        Key Patent Granted in Japan

 Title: “Methods for determining the cause of somatic mutagenesis”


Dec 2017        Key Patent Granted in Europe

 Title: “Methods for determining the cause of somatic mutagenesis”


Sep 2017        Appointment of bioinformatician Dr. Jared Mamrot to the GMDx team


Aug 2017        GMDx receives an “Accelerating Commercialisation” Grant from the Department of Industry, Innovation and Science.

 The grant is in support of a clinical trial for Hepatitis B treatment.


May 2017        GMDx attended the Biomarkers in Immuno-Oncology Congress in Philadelphia, PA.


Oct 2016        Robyn Lindley awarded the R. Douglas Wright medal and presented the oration titled:

The Hunt for the Source of Mutations in Cancer: A story of discovery and innovation at the coalface